News Image

Aptose Reports Year End 2024 Results and Corporate Highlights

Provided By GlobeNewswire

Last update: Mar 28, 2025

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial

Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy

Read more at globenewswire.com
Follow ChartMill for more